Research Output
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF
  Several pyrrolo[2,3-b]pyridine-based B-RAF inhibitors are well known and some of them are currently FDA approved as anticancer agents. Based on the structure of these FDA approved V600E B-RAF inhibitors, two series of pyrrolo[2,3-b]pyridine scaffold were designed and synthesized in attempt to develop new potent V600E B-RAF inhibitors. The 38 synthesized compounds were biologically evaluated for their V600E B-RAF inhibitory effect at single dose (10 μM). Compounds with high percent inhibition were tested to determine their IC 50 over V600E B-RAF. Compounds 34e and 35 showed the highest inhibitory effect with IC 50 values of 0.085 µM and 0.080 µM, respectively. Headed for excessive biological evaluation, the synthesized derivatives were tested over sixty diverse human cancer cell lines. Only compound 35 emerged as a potent cytotoxic agent against different panel of human cancer cell lines.

  • Type:

    Article

  • Date:

    10 April 2020

  • Publication Status:

    Published

  • Publisher

    Elsevier BV

  • DOI:

    10.1016/j.bmc.2020.115493

  • Cross Ref:

    10.1016/j.bmc.2020.115493

  • ISSN:

    0968-0896

  • Funders:

    Historic Funder (pre-Worktribe)

Citation

Abdel-Maksoud, M. S., Ali, E. M., Ammar, U. M., Mersal, K. I., Yoo, K. H., & Oh, C. (2020). Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF. Bioorganic and Medicinal Chemistry, 28(11), Article 115493. https://doi.org/10.1016/j.bmc.2020.115493

Authors

Keywords

B-RAF inhibitors, Kinase inhibitor, Anticancer, Pyrrolo[2,3-b]pyridine, SAR

Monthly Views:

Available Documents